NFG
AIMT

Next Financial Group’s Aimmune Therapeutics AIMT Stock Holding History

Next Financial Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed -$3K – 1599
2017
Q3 		$3K Sell
100
-300
-75% -$6.47K ﹤0.01% 1569
2017
Q2 		$8K Sell
400
-200
-33% -$3.81K ﹤0.01% 1426
2017
Q1 		$12K Hold
600
– – ﹤0.01% 1227
2016
Q4 		$12K Buy
600
+100
+20% +$2.04K ﹤0.01% 1585
2016
Q3 		$8K Buy
500
+300
+150% +$4.05K ﹤0.01% 1784
2016
Q2 		$2K Buy
+200
New +$2.72K ﹤0.01% 1621
2016
Q1 		– Sell
-500
Closed -$9K – 1910
2015
Q4 		$9K Hold
500
– – ﹤0.01% 1229
2015
Q3 		$12K Buy
+500
New +$11.7K ﹤0.01% 1154

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Next Financial Group's AIMT Position: Q4 2017 in Review

Next Financial Group sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 100 shares — an estimated $3K sold.

Next Financial Group first reported a position in AIMT in Q3 2015 and held it in 8 quarters. The position peaked at $12K in Q1 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Next Financial Group reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Next Financial Group sold 100 Aimmune Therapeutics shares in Q4 2017, an estimated $3K.
  • Next Financial Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 8 quarters.
  • Next Financial Group's Aimmune Therapeutics position peaked at $12K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Next Financial Group's 13F filing for Q4 2017, filed 16 Jan 2018.